acute myeloid leukemia
Let an agent explain acute myeloid leukaemia and its subtypes, relay diagnosis, classification, treatment and prognosis from haematology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish AML from acute lymphoblastic leukaemia, chronic myeloid leukaemia and myelodysplastic syndromes.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify
Researched by: Claude
Purpose and description
Let an agent explain acute myeloid leukaemia and its subtypes, relay diagnosis, classification, treatment and prognosis from haematology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish AML from acute lymphoblastic leukaemia, chronic myeloid leukaemia and myelodysplastic syndromes.
A cancer of the blood and bone marrow in which immature myeloid cells proliferate rapidly, classified by genetics and morphology into subtypes such as acute myeloblastic and acute monocytic leukaemia, core binding factor leukaemia with favourable genetics, cases with BCR-ABL1 and rare inherited predispositions, and occurring mainly in adults with rising incidence with age; it is treated with intensive chemotherapy, targeted drugs and stem cell transplantation, and suspected cases need urgent haematology referral.
What it is for: Not applicable; a disease.
It can be explain subtypes; relay diagnosis and treatment; route to clinicians; distinguish related diseases.
Distinguishing features
Myeloid lineage
Rapid course
Genetic classification
Intensive treatment
What it looks like
Not a visible object; fatigue, infections and bleeding from marrow failure.
Physical character
new cases, US: about 20000 per year
median age at diagnosis: about 68 years
WHO classification: 2022 revision note
five-year survival, all ages: about 30 percent - estimates
How it is recognised
Rapid cancer of immature myeloid cells
Acute myeloblastic, acute monocytic, core binding factor, BCR-ABL1 positive, inherited AML
ALL involves lymphoid cells; CML is chronic; MDS is a precursor state
Related models
is a kind of - in registry terms
is a kind of - in registry terms
is contrasted with - of lymphoid cells
is treated with - in many cases
In practice
Families and kinds
AML with defining genetic abnormalities including core binding factor and BCR-ABL1
AML defined by differentiation including myeloblastic and monocytic forms
therapy-related and secondary AML
AML with germline predisposition
rare forms such as myeloid dendritic cell leukaemia
Identifiers
ICD-10 C92.0 acute myeloblastic leukaemia
MeSH D015470 Leukemia, Myeloid, Acute
Standards and regulation
WHO and ICC classifications of myeloid neoplasms
ELN and NCCN treatment guidelines
Drug approvals for targeted therapies
Failure modes and hazards
Delayed referral
Agents giving personal medical advice
Stale treatment and classification information
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.
Understand What AML is.
Clinical.
Definition
Definition and subtypes.
Definition
Definition.
- What is acute myeloid leukaemia, and how do the subtypes named in the registry differ? definition
- Is the user asking about their own or a family member s diagnosis, which needs a haematologist? boundary
Causes
Causes and risk.
Causes
Causes.
- What causes AML, including prior therapy, genetics and inherited predisposition, in general terms? provenance
- Which entry fits the specific subtype? action
Care Diagnosis and treatment.
Clinical.
Diagnosis
Diagnosis and classification.
Diagnosis
Diagnosis.
- How is AML diagnosed and classified with marrow examination, flow cytometry and genetics, as guidelines describe? provenance
- Which references are standard? provenance
Treatment
Treatment.
Treatment
Treatment.
- What treatments do guidelines recommend, from induction chemotherapy to targeted drugs and transplantation, in general terms? provenance
- Which sources are cited? provenance
Support Living with AML.
Application.
Prognosis
Prognosis.
Prognosis
Prognosis.
- How do genetics and age affect prognosis, as guidelines report? provenance
- Is the user seeking personal prognosis, which needs their clinician? boundary
Organisations
Support organisations.
Organisations
Organisations.
- Where can patients find leukaemia organisations and clinical trials? action
- Which entry fits leukaemia support organisations? action
Context Research and epidemiology.
Context.
Research
Research.
Research
Research.
- What research directions exist in AML, with findings attributed? provenance
- Which entry fits targeted therapy? action
Epidemiology
Epidemiology.
Epidemiology
Epidemiology.
- How common is AML, and how do rates vary by age and region? provenance
- Which entry fits the epidemiology of leukaemia? action
What the second pass must settle
- Should the genetic subtypes be separate entries?
- How should haematology guidelines be linked?
- The registry entry has merged aliases naming subtypes; should they be split off?